DNMT3B (DNA (cytosine-5-)-methyltransferase 3 beta) is a key enzyme involved in the process of DNA methylation, a critical epigenetic modification that regulates gene expression, development, and genome integrity. DNMT3B is unique in its role during early embryogenesis and de novo methylation, meaning that it establishes new DNA methylation patterns on previously unmethylated cytosine residues. This enzymatic activity is essential for normal development, genomic imprinting, and X chromosome inactivation in mammals. Unlike DNMT1, which primarily maintains methylation during DNA replication, DNMT3B targets both symmetric CpG sites and non-CpG environments, increasing the complexity and specificity of epigenetic regulation.
Mutations in the DNMT3B gene have been associated with various diseases, most notably immunodeficiency, centromere instability, and facial anomalies (ICF) syndrome. ICF syndrome is a rare autosomal recessive disorder characterized by immune deficiency, facial anomalies, and chromosomal instability, which emphasizes the important role of this enzyme in maintaining genomic stability and normal physiological function. In addition to its developmental role, DNMT3B has also been implicated in cancer. Aberrant expression and mutations of DNMT3B are frequently observed in various malignancies, where they lead to dysregulated gene expression and thus tumorigenesis. This makes DNMT3B both a potential biomarker for cancer prognosis and a target for epigenetic therapy.
Mouse embryonic fibroblasts derived from DNMT3b knockout embryos exhibit DNA damage and chromosomal instability, suggesting that DNMT3b plays a key role in genomic stability. Loss-of-function mutations in DNMT3b are specifically seen in a rare human genetic disorder, immunodeficiency-centromere instability-facial dysmorphism (ICF type 1) syndrome. Studies have shown that DNMT3b is recruited to GC-rich (pericentromeric) regions to maintain chromosomal stability through interaction with the centromeric protein CENP-C. Thus, the major genomic regions affected by DNMT3b loss-of-function in ICFs are pericentromere noncoding repetitive elements, where GC regions are hypomethylated, coinciding with the centromeric DNA breaks observed in ICF cells. However, how DNMT3b dysfunction increases DNA damage and centromeric instability remains an open question.
In this study, the researchers used human DNMT3B Knockout Cell Line-HCT116, in which both alleles of DNMT3b were interrupted by homologous recombination, and ICF cells carrying a DNMT3b loss-of-function mutation to address this question. Analysis revealed that R-loops are responsible for the significant DNA damage signature observed in DNMT3b knockout in HCT116 (BKO) and DNMT3b loss-of-function mutations in ICF lymphocytes. Sites of DNA damage in BKO cells were mapped to repetitive satellite sequences and rDNA genes. In BKO and ICF cells, (peri)centromeric R-loops are cleaved and removed by the endonucleases XPG and XPF. Depletion of XPG and XPF resulted in an increase in R-loops and a decrease in γH2AX associated with (peri)centromeric DNA sequences in both BKO and ICF cells. DNMT3b dysfunction significantly increased the sensitivity of R-loops to the cleavage process. Finally, the study showed that DNA double-strand breaks (DSBs) at centromeres may be repaired via an error-prone end-joining pathway in ICF cells. Thus, DNMT3 dysfunction compromises centromere integrity via R-loop-mediated DNA damage and repair.
Figure 1.R-loops are the sources of DNA damage in DNMT3B Knockout Cell Line-HCT116 (BKO) and ICF cells. (Shih, Hsueh-Tzu, et al. 2022)
The DNMT3B gene encodes DNA methyltransferase 3β, an enzyme that is essential for de novo DNA methylation and regulation of gene expression. DNMT3B knockout cell line-HCT116 has become valuable tools for a variety of research applications. Here are some important applications:
Epigenetic Research: DNMT3B knockout cell lines facilitate the study of DNA methylation patterns and how they affect gene expression, epigenetic modifications, and cellular processes such as differentiation and development.
Cancer Research: DNMT3B knockout HCT116 cells facilitate the understanding of the role of DNMT3B in tumorigenesis. Researchers use these cells to explore how changes in DNA methylation contribute to cancer initiation, progression, and resistance to therapy.
Genetic Disease Research: This cell line is used to study genetic diseases associated with abnormal DNA methylation, such as ICF (immunodeficiency, centromere instability, and facial anomalies) syndrome, which is associated with DNMT3B mutations.
Drug Development: DNMT3B knockout HCT116 cells can be used to screen and develop drugs that target the DNA methylation pathway. These cells can help identify compounds that may modulate DNA methylation for therapeutic effects.
Developmental Biology: This cell line can serve as a model to study the effects of DNMT3B loss during cell differentiation. This can help understand the role of DNA methylation during development and may have implications for regenerative medicine and stem cell research.
Customer Q&As
What is the recommended growth medium? Does it require antibiotic selection?
A: DMEM supplemented with 10% fetal bovine serum.
It is not required to add the selection antibiotics when culturing the KO cells.
How is the knockout cell line validated?
A: The knockout cell product is validated by PCR amplification and Sanger Sequencing to confirm the mutation at the genomic level. Please find the detailed mutation info in the datasheet.
Is the product a single clonal cell or mixed cell pool?
A: Single clonal cell.
Can I confirm gene knockout by RT-qPCR?
A: No. This knockout cell product is generated using the CRISPR/Cas9 system to induce small insertions or deletions (indels) resulting in frameshift mutations. Although these frameshift mutations typically disrupt the coding gene, there is a possibility that the non-functional transcript may still be transcribed. Consequently, this could potentially yield misleading results when analyzed by RT-qPCR.
How can I store the cell product?
A: The cell line should be stored in liquid nitrogen for long-term preservation.
Is it possible to get multiple knockout clones for my GOI?
A: For most cases, we often keep at least 2 clones with different frameshift mutations. Please feel free to contact us to check if there are additional available clones.
Ask a Question
Customer Reviews
Invaluable tool
DNMT3B knockout cells lack the DNMT3B gene's expression and, therefore, have reduced DNA methylation activity. This cell line is very helpful for my research.
United Kingdom
02/23/2023
Helpful
We are investigating the use of DNMT3B knockout cells in breast cancer therapy. Good experimental results were obtained. I recommend it.
Reliable results
I have used several gene knockout reagents in the past, but Human DNMT3B Knockout Cell Line-HCT116 is the best by far. It is very easy to use and produces reliable results.
United Kingdom
02/23/2023
Streamline experiments
The knockdown efficiency of Human DNMT3B Knockout Cell Line-HCT116 is simply amazing. It has made my experiments much more efficient and streamlined.
Productive
I am so glad that I discovered Human DNMT3B Knockout Cell Line-HCT116. It has made my research much more productive, and the results are always consistent.
Effective
I cannot recommend Human DNMT3B Knockout Cell Line-HCT116 enough. It is incredibly effective and has made a huge difference in my research.
Great results
Human DNMT3B Knockout Cell Line-HCT116 has made gene editing so much simpler. It is easy to use and consistently produces great results.
Write a Review